6310-17-4

Basic information

• Product Name: 2-bromo-4-nitro-1-tert-butyl-benzene
• Synonyms: 2-bromo-4-nitro-1-tert-butyl-benzene;2-BROMO-1-TERT-BUTYL-4-NITROBENZEN;2-bromo-1-(tert-butyl)-4-nitrobenzene(WX191811)
• CAS NO: 6310-17-4
• Molecular Formula: C₁₀H₁₂BrNO₂
• Molecular Weight: 258.11
• Mol File: 6310-17-4.mol
• Article Data: 16

Chemical Properties

• Melting Point: 93-94 °C
• Boiling Point: 298°C at 760 mmHg
• Flash Point: 134°C
• Appearance: /
• Density: 1.401g/cm³
• Vapor Pressure: 0.00232mmHg at 25°C
• Refractive Index: 1.552
• CAS DataBase Reference: 2-bromo-4-nitro-1-tert-butyl-benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-nitro-1-tert-butyl-benzene(6310-17-4)
• EPA Substance Registry System: 2-bromo-4-nitro-1-tert-butyl-benzene(6310-17-4)

Safety Data

• Hazardous Substances Data: 6310-17-4(Hazardous Substances Data)

Usage

General Description

2-bromo-4-nitro-1-tert-butyl-benzene is an organic compound that contains a benzene ring substituted with a bromine atom, a nitro group, and a tert-butyl group. It is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. The presence of the bromine and nitro groups make it a versatile building block for the synthesis of more complex molecules. Its tert-butyl group also makes it a useful reagent for organic synthesis, as it can undergo various reactions to form different compounds. Due to its structural characteristics, 2-bromo-4-nitro-1-tert-butyl-benzene has a wide range of potential applications in the pharmaceutical, agrochemical, and other industries.

InChI:InChI=1/C10H12BrNO2/c1-10(2,3)8-5-4-7(12(13)14)6-9(8)11/h4-6H,1-3H3

Upstream product

• 253185-03-4 tert-butylbenzene 
• 3282-56-2 4-tert-butylnitrobenzene 

Downstream Products

• 873056-28-1 2-(tert-butyl)-5-nitrobenzonitrile 
• 873056-34-9 methyl 2-tert-butyl-5-aminobenzoate 
• 873056-38-3 (2-tert-butyl-5-aminophenyl)methanol 
• 1610416-92-6 2-(tert-butyl)-5-(methoxymethyl)benzonitrile 
• 1369886-14-5 5-bromo-2-(tert-butyl)benzonitrile 
• 873056-33-8 methyl 2-tert-butyl-5-nitrobenzoate 
• 14034-90-3 2-tert-butyl-5-nitrobenzoic acid 
• 873056-32-7 tert-butyl 2-tert-butyl-5-aminobenzylcarbamate 
• 873056-31-6 tert-butyl 2-tert-butyl-5-nitrobenzylcarbamate 
• 873056-30-5 (2-tert-butyl-5-nitrophenyl)methanamine 
• 873056-29-2 5-amino-2-(tert-butyl)benzonitrile 
• 103275-21-4 3-bromo-4-(tert-butyl)aniline 
• 453560-95-7 4-(2-tert-butyl-5-nitro-phenyl)-but-3-en-1-ol 
• 1135494-90-4 1-[4-bromo-5-(tert-butyl)-2-nitrophenyl]-4-methylpiperazine 

Relevant articles and documents

Nucleophilic Iron Complexes in Proton-Transfer Catalysis: An Iron-Catalyzed Dimroth Cyclocondensation

The nucleophilic iron complex Bu4N[Fe(CO)3(NO)] (TBA[Fe]) is an active catalyst in C?H-amination but also in proton-transfer catalysis. Herein, we describe the successful use of this complex as a proton-transfer catalyst in the cyclocondensation reaction between azides and ketones to the corresponding 1,2,3-triazoles. Cross-experiments indicate that the proton-transfer catalysis is significantly faster than the nitrene-transfer catalysis, which would lead to the C?H amination product. An example of a successful sequential Dimroth triazole–indoline synthesis to the corresponding triazole-substituted indolines is presented.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.